NRx Pharma welcomes Trump order to speed psychedelic drug approvals for mental illness

• NRx Pharmaceuticals welcomed April 18, 2026 Executive Order signed by President Trump aimed at accelerating research and lowering approval barriers for psychedelic medications targeting depression, PTSD, suicidality.
• Order directs FDA commissioner to issue Commissioner’s National Priority Vouchers to qualifying psychedelic drugs with Breakthrough Therapy designation; NRx applied for a voucher to support planned NRX-100 New Drug Application.
• NRX-100, preservative-free intravenous ketamine, holds FDA Fast Track designation for depression patients with suicidal ideation, including bipolar depression.
• Order also calls for HHS and FDA collaboration with VA and private sector to expand trial participation and real-world evidence use, supporting NRx plan to leverage existing federally funded trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.